Elucidating the underlying causes of the individually different treatment responses in order to develop new therapeutic or diagnostic concepts based on the findings, is a fundamental goal of Research Area 2.
To achieve this goal, it is essential to understand the molecular mechanisms that drive tumor development and progression.
Research Area 2 combines the expertise in structural biology, biochemistry and cell biology within the FCI to analyze the tumorigenesis, the response to therapy and resistance mechanisms systematically and functionally in the overall cellular context at the molecular level.
In line with the interdisciplinarity of the FCI, the molecular-pathophysiological mechanisms that underlie the clinical observations are elaborated on the basis of individual tumor samples.
The close integration of basic scientists with clinicians ensures the focus on clinically relevant issues, access to individual tumor samples and to a broad repertoire of functional tests.